Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients

NCT03690115 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG: Ponatinib 30 MG

Sponsor

Versailles Hospital